Literature DB >> 17164044

Taxanes in breast cancer: an update.

Alison K Conlin1, Andrew D Seidman.   

Abstract

Over the past decade the taxanes have proved to be fundamental in the treatment of breast cancer. Initially found to have efficacy in metastatic breast cancer, the taxanes are now vital components in the treatment of early-stage disease, in which their addition to adjuvant treatment of early breast cancer has been shown to improve overall survival. In addition, the taxanes have demonstrated a role in first-line therapy for metastatic disease, with some of the highest efficacy of any class of chemotherapy. Targeted therapies in combination with the taxanes have further improved survival for both early and metastatic disease. New formulations of taxanes may both improve antitumor activity and reduce toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17164044     DOI: 10.1007/bf02951422

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  38 in total

1.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.

Authors:  P Viens; H Roché; P Kerbrat; P Fumoleau; J P Guastalla; T Delozier
Journal:  Am J Clin Oncol       Date:  2001-08       Impact factor: 2.339

3.  Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

Authors:  Nuhad K Ibrahim; Brian Samuels; Ray Page; Dinesh Doval; Kirtikumar M Patel; S C Rao; Madhavan Krishnan Nair; Paul Bhar; Neil Desai; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

Authors:  S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

Authors:  P M Ravdin; H A Burris; G Cook; P Eisenberg; M Kane; W A Bierman; J Mortimer; E Genevois; R E Bellet
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

9.  Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Authors:  A D Seidman; B S Reichman; J P Crown; T J Yao; V Currie; T B Hakes; C A Hudis; T A Gilewski; J Baselga; P Forsythe
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Authors:  L Gianni; E Munzone; G Capri; F Villani; C Spreafico; E Tarenzi; F Fulfaro; A Caraceni; C Martini; A Laffranchi
Journal:  J Natl Cancer Inst       Date:  1995-08-02       Impact factor: 13.506

View more
  14 in total

1.  Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.

Authors:  Xinrong Guo; Sibylle Loibl; Michael Untch; Volker Möbus; Kathrin Schwedler; Peter A Fasching; Jana Barinoff; Frank Holms; Christoph Thomssen; Dirk M Zahm; Rolf Kreienberg; Maik Hauschild; Holger Eidtmann; Sascha Tauchert; Keyur Mehta; Gunter von Minckwitz
Journal:  Breast Care (Basel)       Date:  2011-08-19       Impact factor: 2.860

2.  A prospective study of docetaxel-associated pain syndrome.

Authors:  Nicholas Chiu; Liying Zhang; Rebecca Dent; Angie Giotis; Jenna van Draanen; Daniela Gallo-Hershberg; Leonard Chiu; Ronald Chow; Bo Angela Wan; Mark Pasetka; Jordan Stinson; Erica Stacey; Sunil Verma; Henry Lam; Edward Chow; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2017-07-22       Impact factor: 3.603

3.  Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer.

Authors:  Jing Wu; Coral Omene; Jerzy Karkoszka; Maarten Bosland; Jonathan Eckard; Catherine B Klein; Krystyna Frenkel
Journal:  Cancer Lett       Date:  2011-05-13       Impact factor: 8.679

4.  Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.

Authors:  Guenther G Steger; Jitka Abrahámová; Florin Bacanu; Stephen Brincat; Arija Brize; Alvydas Cesas; Tanja Cufer; Magdolna Dank; Renata Duchnowska; Alexandru Eniu; Jacek Jassem; Zsuzsanna Kahán; Erika Matos; Peeter Padrik; Signe Plāte; Helis Pokker; Gunta Purkalne; Constanta Timcheva; Valentina Tzekova; Rostislav Vyzula; Christoph C Zielinski
Journal:  Wien Klin Wochenschr       Date:  2010-06-15       Impact factor: 1.704

5.  Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.

Authors:  Michael C Cochran; John Eisenbrey; Richard O Ouma; Michael Soulen; Margaret A Wheatley
Journal:  Int J Pharm       Date:  2011-05-13       Impact factor: 5.875

Review 6.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

Review 7.  Treatment options for breast cancer resistant to anthracycline and taxane.

Authors:  Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

8.  Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience.

Authors:  Orhan Onder Eren; Mehmet Artac; Melih Cem Boruban; Ozlem Yavas; Ugur Arslan; Metin Basaranoglu
Journal:  Med Oncol       Date:  2008-11-20       Impact factor: 3.064

9.  Migration Rate Inhibition of Breast Cancer Cells Treated by Caffeic Acid and Caffeic Acid Phenethyl Ester: An In Vitro Comparison Study.

Authors:  Agata Kabała-Dzik; Anna Rzepecka-Stojko; Robert Kubina; Żaneta Jastrzębska-Stojko; Rafał Stojko; Robert Dariusz Wojtyczka; Jerzy Stojko
Journal:  Nutrients       Date:  2017-10-19       Impact factor: 5.717

10.  Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials.

Authors:  Yun Liu; Guoxin Ye; Dali Yan; Lei Zhang; Fan Fan; Jifeng Feng
Journal:  Oncotarget       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.